Michigan State University researchers use AI and nanomedicine to identify blood-based biomarkers for prostate cancer and atherosclerosis.
Key Details
- 1Researchers from MSU, Augusta University, Karolinska Institute, and Stanford developed a new diagnostic platform.
- 2The method combines nanomedicine, AI, and causal analysis to identify rare plasma protein biomarkers.
- 3Initial targets were metastatic prostate cancer and atherosclerosis (clogged arteries).
- 4Published in the Chemical Engineering Journal on April 1, 2025.
- 5Funding from the American Heart Association, DoD Prostate Cancer Research, NIH, and NSF.
Why It Matters
Integrating radiology expertise with AI-driven biomarker discovery could transform early detection and precision medicine, providing radiologists with novel tools for non-invasive disease diagnosis. These advances support the radiology-AI community's efforts to enhance diagnostic accuracy and patient stratification.
Source
EurekAlert
Related News
•EurekAlert
MD Anderson Unveils New AI Genomics Insights and Therapeutic Advances
MD Anderson reports breakthroughs in cancer therapeutics and provides critical insights into AI models for genomic analysis.
•EurekAlert
UCLA Researchers Present AI, Blood Biomarker Advances at SABCS 2025
UCLA Health researchers unveil major advances in breast cancer AI pathology, liquid biopsy, and biomarker strategies at the 2025 SABCS.
•EurekAlert
SH17 Dataset Boosts AI Detection of PPE for Worker Safety
University of Windsor researchers released SH17, a 8,099-image open dataset for AI-driven detection of personal protective equipment (PPE) in manufacturing settings.